Effect of famotidine in combination with antiepileptic drugs on locomotor activity in mice
PDF

Keywords

exploratory locomotor activity
spontaneous locomotor activity
antiepileptic drugs
famotidine
safety profile

Abstract

Histamine type 2 receptor antagonists are one of the most commonly used agents to treat peptic ulcer disease. Since patients with epilepsy may have many comorbidities, the aim of this study was to investigate the influence of one of the strongest second generation histamine type 2 receptor antagonist, famotidine, on the exploratory and spontaneous activity in mice after 1 or 7 days treatment. Additionally, the interaction between famotidine and antiepileptics: carbamazepine, phenytoin, phenobarbital or valproate and their effect on animals activity was also evaluated. Locomotor activity was monitored electronically using a Digiscan analyzer in relation to ambulatory and rearing activities, as well as total distance travelled by animals during 15 minute periods. Results of our study indicate that famotidine administered alone did not modulate three variables of exploratory motor activity (horizontal activity, total distance and vertical activity) in mice. On the other hand, famotidine co-administered with valproate (1 day) or phenobarbital (1 day or 7 days) worsened vertical activity in mice in exploratory time. Similarly, impairment in horizontal activity in mice was observed when famotidine was given with phenobarbital (1 or 7 days). An increase in total distance in mice after famotidine alone or in combination with tested antiepileptic drugs was also shown. Moreover, famotidine alone or together with antiepileptic agents significantly impaired spontaneous locomotor activity in mice. The presented results show that famotidine administration to patients with epilepsy should be considered as potentially hazardous.

PDF

References

1. Wada H, Inagaki N, Itowi N, Yamatodani A. Histaminergic neuron system in the brain: distribution and possible functions. Brain Res Bull. 1991;27(3-4):367-70.

2. Wyngaarden JB, Seevers MH. The toxic effects of antihistaminic drugs. J Am Med Assoc. 1951;145(5):277-82.

3. Churchill JA, Gammon GD. The effect of antihistaminic drugs on convulsive seizures. J Am Med Assoc. 1949;141(1):18-21.

4. Gerald MC, Richter NA. Studies on the effects of histaminergic agents on seizure susceptibility in mice. Psychopharmacologia. 1976; 46(3):277-82.

5. Tuomisto L, Tacke U. Is histamine an anticonvulsive inhibitory transmitter? Neuropharmacology. 1986;25(8):955-8.

6. Scherkl R, Hashem A, Frey HH. Histamine in brain-its role in regulation of seizure susceptibility. Epilepsy Res. 1991;10(2-3):111-8.

7. Świąder M, Kalisz A, Porebiak J, Kleinrok Z, Czuczwar SJ. Influence of antazoline on the anticonvulsant activity of conventional antiepileptic drugs against maximal electroshock-induced seizures in mice. Pol J Pharmacol. 1999;51(1):104.

8. Świąder M, Chwalczuk K, Wielosz M, Czuczwar SJ. Influence of chronic treatment with H1 receptor antagonists on the anticonvulsant activity of antiepileptic drugs. Pol J Pharmacol. 2001;53(1):93-6.

9. Świąder MJ, Łuszczki JJ, Wielosz M, Czuczwar SJ. Effect of histamine receptor antagonists on aminophylline-induced seizures and lethality in mice. Pharmacol Rep. 2005;57(4):531-5.

10. Świąder MJ, Czuczwar SJ. Interaction of famotidine, an H2 histamine receptor antagonist, with conventional antiepileptic drugs in mice. Pharmacol Rep. 2014;66(3):485-91.

11. Oyewumi LK, Vollick D, Merskey H, Plumb C. Famotidine as an adjunct treatment of resistant schizophrenia. J Psychiatry Neurosci. 1994;19(2):145-50.

12. Yuan RY, Kao CR, Sheu JJ, Chen CH, Ho CS. Delirium following a switch from cimetidine to famotidine. Ann Pharmacother. 2001; 35(9):1045-8.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.

Copyright (c) 2019 Autors

Downloads

Download data is not yet available.